Pregnancy rates among infertile women have been reported to increase after hysterosalpingography, but it is unclear whether the type of contrast medium used (oil-based or water-soluble contrast) influences this potential therapeutic effect.
T h e ne w e ngl a nd jou r na l o f m e dicine I nfertility, which is defined as the inability to conceive after 1 year of unprotected intercourse, affects approximately one of every six couples who are trying to get pregnant. 1 Hysterosalpingography to assess tubal patency is part of the infertility evaluation in many cases. Although hysterosalpingography was introduced as a diagnostic test, it has been suggested that tubal flushing directly increases pregnancy rates in the months after hysterosalpingography. 2 Many studies have shown a fertility-enhancing effect of hysterosalpingography with the use of oil contrast, 3 but few randomized, controlled trials have assessed this effect. [4] [5] [6] A meta-analysis of three trials showed higher rates of ongoing pregnancy after hysterosalpingography performed with oil contrast than after no intervention (odds ratio, 3.6; 95% confidence interval [CI], 2.1 to 6.3). 7 Five randomized, controlled trials directly compared pregnancy rates after hysterosalpingography involving oil contrast with those after hysterosalpingography involving water contrast. [8] [9] [10] [11] [12] Four of these trials showed no significant difference in ongoing pregnancy rates associated with the two contrast mediums used, [8] [9] [10] 12 but one trial showed a higher ongoing pregnancy rate after hysterosalpingography with oil contrast than with water contrast (odds ratio, 3.5; 95% CI, 2.0 to 6.0). 11 A meta-analysis including all five trials did not show significantly higher rates of pregnancy among women who underwent hysterosalpingography with oil contrast than among those who underwent this procedure with water contrast (odds ratio, 1.4; 95% CI, 0.8 to 2.5). 7 However, the included studies were considered to be of low quality, the method of randomization [9] [10] [11] and whether there was blinding of treatment assignments [8] [9] [10] [11] [12] were unclear, and some studies indicated that rates of loss to follow-up were as high as 21%. 8, 10 Moreover, the largest trial, which included 533 participants, showed no significant difference in live-birth rates with the use of oil contrast as compared with water contrast. 12 In view of this uncertainty, we conducted a multicenter, randomized, controlled trial to compare ongoing pregnancy rates and other pregnancy outcomes among women who underwent hysterosalpingography with oil contrast with those among women who underwent this procedure with water contrast.
Me thods

Trial Oversight
The Water versus Oil (H2Oil) trial was approved by the ethics committee and institutional review board of the Academic Medical Center, Amsterdam, and by the board of directors of all participating hospitals. Trial oversight was provided by the ethics committee of the Academic Medical Center. In each of the participating centers, data monitoring in accordance with the Good Clinical Practice guidelines was performed by dedicated research nurses. All participants provided written informed consent. The first, second, and last authors vouch for the accuracy and completeness of the data and analyses and for the fidelity of the trial to the protocol, which is available with the full text of this article at NEJM.org.
Trial Participants
Participants in the H2Oil trial were recruited from 27 hospitals (4 academic, 12 teaching, and 11 nonteaching hospitals) in the Netherlands. Gynecologists in these hospitals collaborate in a nationwide consortium for women's health research (the Dutch Consortium for Healthcare Evaluation and Research in Obstetrics and Gynecology; www.studies-obsgyn.nl).
Women were eligible to participate in the trial if they were between 18 and 39 years of age, had spontaneous menstrual cycles, and had been trying to conceive for at least 1 year and if there was an indication for evaluation of tubal patency by means of hysterosalpingography.
13 Exclusion criteria were known endocrine disorders (e.g., the polycystic ovary syndrome, diabetes, hyperthyroidism, and hyperprolactinemia), less than eight menstrual cycles per year, a high risk of tubal disease (as indicated by a history of pelvic inflammatory disease, previous chlamydia infection, or known endometriosis), iodine allergy (since the contrast mediums under study both contained iodine), and a total motile sperm count after sperm wash of less than 3 million sperm per milliliter in the male partner (or a total motile sperm count of <1 million sperm Oil or Water Contr ast for Hysterosalpingogr aphy per milliliter when an analysis after sperm wash was not performed).
Randomization and Trial Intervention
Potential participants were informed about the trial by their doctors or dedicated research nurses. After they provided written informed consent, the women were, preferably just before hysterosalpingography, randomly assigned in a 1:1 ratio to the use of oil contrast (Lipiodol UltraFluid, Guerbet) (the oil group) or water contrast (Telebrix Hystero, Guerbet) (the water group). Randomization was performed by the doctors or research nurses with the use of a secured online randomization program (ALEA, FormsVision) with random block sizes of 2, 4, or 6, stratified according to hospital. This randomization program was overseen by an independent data manager. Owing to the difference in imaging between the use of oil-based contrast and waterbased contrast, and, since our outcome of ongoing pregnancy was objective, the trial was not blinded with respect to participants and caregivers.
Hysterosalpingography was performed according to local protocols. The contrast medium could be infused into the uterus with the use of a cervical vacuum cup, metal cannula (hysterophore), or balloon catheter. During the infusion of approximately 5 to 10 ml of contrast medium, four to six radiographs that were obtained to evaluate the patency of both fallopian tubes were examined by a gynecologist or radiologist.
Subsequently, couples received expectant management or the women underwent intrauterine insemination. Expectant management was indicated when the predicted likelihood of natural conception within 12 months after hysterosalpingography, as based on the prognostic model of Hunault, 14, 15 was 30% or greater. Intrauterine insemination was offered when this likelihood was less than 30%, when mild male infertility (defined as a total motile sperm count between 1 million and 3 million sperm per milliliter) was present, or after a period of expectant management without natural conception. Intrauterine insemination was initiated after a minimum of 2 months of expectant management after hysterosalpingography and could be performed with or without mild ovarian hyperstimulation, according to local protocols. Mild ovarian hyperstimulation, aiming for two or three follicles, was achieved with clomiphene citrate or exogenous gonadotropins.
Outcome Measures
The primary outcome measure was ongoing pregnancy, defined as a positive fetal heartbeat on ultrasonographic examination after 12 weeks of gestation, with the first day of the last menstrual cycle for the pregnancy within 6 months after randomization. Secondary outcome measures were clinical pregnancy (defined as a gestational sac detected on ultrasonography), live birth (defined as a live birth after 24 weeks of gestation), miscarriage (defined as the absence of a fetal heartbeat on ultrasonography or spontaneous loss of pregnancy before 12 weeks of gestation), ectopic pregnancy (defined as an embryo implanted outside the uterine cavity), and pain scores after hysterosalpingography, measured by means of the Visual-Analogue Scale for Pain (scores range from 0.0 to 10.0 cm, with higher scores indicating more severe pain).
Costs were a prespecified secondary outcome, but this analysis is not included in this article. We also compared the time to pregnancy resulting in an ongoing pregnancy (calculated from the first day of the last menstrual period plus 4 weeks).
Statistical Analysis
We calculated that the trial would need to include 1080 women (540 in each group) to obtain a power of 80%, with an alpha error of 5%, to detect a difference of 7 percentage points between the trial groups in rates of ongoing pregnancies. This difference was considered by the clinical investigators to be clinically meaningful, over an anticipated control rate of 18% after hysterosalpingography. 10, 11 Since the trial compared two interventions used routinely in clinical practice and was expected to recruit quickly, an interim analysis was not performed.
Categorical data were reported as absolute numbers and percentages. Normally distributed continuous variables were summarized as means with standard deviations, and nonnormally distributed continuous variables were reported as medians with interquartile ranges. Apart from T h e ne w e ngl a nd jou r na l o f m e dicine conventional baseline data, we also compared the likelihood of natural conception within 12 months after hysterosalpingography (calculated with the use of the prognostic model of Hunault) in the two trial groups after completion of the fertility workup to see whether the chance of getting pregnant was similar in the two groups. 14, 15 All data were analyzed according to the intention-to-treat principle. Univariate rate ratios or relative risks and 95% confidence intervals were calculated for the primary and other binary outcome measures, and the chi-square test was used to assess statistical significance. Continuous outcomes were analyzed with the use of an independent t-test or the Mann-Whitney U-test as appropriate. We used Kaplan-Meier curves with a log-rank test to compare the groups with respect to the time to pregnancy resulting in an ongoing pregnancy. Two-sided P values of less than 0.05 were considered to indicate statistical significance. No adjustment was made for multiple comparisons. SPSS software, version 22.0 (IBM), and R software, version 3.3.1 (R Project for Statistical Computing), were used for statistical analyses. Between February 3, 2012, and October 29, 2014, a total of 1294 infertile women were screened for eligibility in the trial, of whom 1240 met the inclusion criteria and 1119 provided written informed consent (Fig. 1 ). Among these 1119 women, 557 were randomly assigned to hysterosalpingography with the use of oil contrast and 562 were assigned to hysterosalpingography with the use of water contrast. At 6 months after randomization, data on the primary outcome, ongoing pregnancy, were available for 1108 of 1119 women (99.0%). Since the number of missing values was very low, we did not impute missing data, and we report on 1108 women (554 women in each group). A total of 71 women (38 women in the oil group and 33 in the water group) did not meet the inclusion criteria after assignment, mostly because of a period of infertility of slightly less than 1 year (Fig. 1) ; these women were included in the analyses. The baseline characteristics were similar in the two groups (Table 1) . A total of 787 women underwent hysterosalpingography on the day of randomization; the remaining women underwent hysterosalpingography more than 1 day (inter- * There were no significant differences (P<0.05) between the two groups in any of the baseline characteristics. IQR denotes interquartile range. † The body-mass index is the weight in kilograms divided by the square of the height in meters. ‡ Race was reported by the clinicians. § Data on maternal smoking were missing for 36 women in the oil group and 26 women in the water group.
Table 1. Baseline Characteristics of the Trial Participants.*
T h e ne w e ngl a nd jou r na l o f m e dicine quartile range, 2 to 10) after randomization. Hysterosalpingography showed bilateral tubal patency in 477 of 554 women randomly assigned to oil contrast (86.1%) and in 491 of 554 women randomly assigned to water contrast (88.6%) (rate ratio, 0.97; 95% CI, 0.93 to 1.02) ( Table S1 in the Supplementary Appendix, available at NEJM.org). Bilateral tubal occlusion occurred in 9 women in the oil group (1.6%) and in 13 women in the water group (2.3%) (relative risk, 0.69; 95% CI, 0.30 to 1.61).
A total of 58.3% of the women who were randomly assigned to oil contrast and 57.2% of the women who were randomly assigned to water contrast received expectant management (Table 2 ). Similar percentages of women in the oil group and the water group underwent intrauterine insemination (39.7% and 41.0%, respectively), in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) (2.3% and 2.2%), laparoscopy (6.2% in each group), and hysteroscopy (4.4% and 4.2%). Indications for IVF or ICSI, laparoscopy, and hysteroscopy are summarized in Table S2 in the Supplementary Appendix. 
Outcomes
The primary outcome, ongoing pregnancy, occurred in 220 of 554 women (39.7%) randomly assigned to oil contrast and in 161 of 554 women (29.1%) randomly assigned to water contrast (rate ratio, 1.37; 95% CI, 1.16 to 1.61; P<0.001).
The median time to the onset of pregnancy was 2.7 months (interquartile range, 1.5 to 4.7) in the oil group and 3.1 months (interquartile range, 1.6 to 4.8) in the water group (P = 0.44) (Fig. 2) . Of the 220 ongoing pregnancies in the oil group, 162 (73.6%) were naturally conceived, 15 (6.8%) were conceived after intrauterine insemination without mild ovarian hyperstimulation, 39 (17.7%) were conceived after intrauterine insemination with mild ovarian hyperstimulation, and 4 (1.8%) were conceived after embryo transfer following IVF or ICSI. Of the 161 ongoing pregnancies in the water group, 117 (72.7%) were naturally conceived, 16 (9.9%) were conceived after intrauterine insemination without mild ovarian hyperstimulation, 26 (16.1%) were conceived after intrauterine insemination with mild ovarian hyperstimulation, and 2 (1.2%) were conceived after embryo transfer following IVF or ICSI.
A total of 214 of 552 women in the oil group (38.8%) versus 155 of 552 women in the water group (28.1%) had a live birth (rate ratio, 1.38; Data on four participants (three in the oil group and one in the water group) were not included because information on the first day of the last menstrual period before an ongoing pregnancy was missing for these participants. The shaded areas indicate 95% confidence intervals. T h e ne w e ngl a nd jou r na l o f m e dicine 95% CI, 1.17 to 1.64; P<0.001). The other secondary outcomes are listed in Table 3 . A post hoc analysis excluding the 71 women who in retrospect did not meet inclusion criteria yielded results that were similar to those in the intention-to-treat analysis for ongoing pregnancy at 6 months (rate ratio, 1.39; 95% CI, 1.17 to 1.65). A total of 3 of 554 women (0.5%) randomly assigned to oil contrast and 4 of 554 women (0.7%) randomly assigned to water contrast had an adverse event during the trial period (Table  S4 in the Supplementary Appendix). In the oil group, 2 women who had an ectopic pregnancy underwent a laparoscopic unilateral salpingectomy. One woman had a molar pregnancy and underwent a vacuum curettage. In the water group, 2 women had an ectopic pregnancy and underwent a laparoscopic unilateral salpingectomy. One woman had a nosebleed after a Puregon injection during intrauterine insemination. In another woman, contrast material was seen in the urinary bladder during hysterosalpingography, and this material disappeared spontaneously. Three women (1.4%), all in the oil group, delivered a child with a congenital anomaly (Table S4 in the Supplementary Appendix).
Discussion
In this multicenter, randomized trial, we found that the rate of ongoing pregnancy within 6 months after randomization was significantly higher among infertile women who underwent hysterosalpingography with oil contrast than among women who underwent this procedure with the use of water contrast. The subsequent live-birth rate was also significantly higher among women who underwent hysterosalpingography with oil contrast.
Our trial has some limitations. The trial was not conducted in a blinded manner, since the doctor who administered contrast material also evaluated the patency of the fallopian tubes during the examination, and oil and water contrast provide different images on radiographs. However, our primary end point, ongoing pregnancy, was objective, and the number of women who underwent intrauterine insemination or IVF or ICSI was similar in the two groups, which makes it unlikely that a lack of blinding influenced our findings. Also, 38 women in the oil group and 33 women in the water group did not meet the inclusion criteria. However, the proportion of these women was similar in the two groups, and results were similar when we excluded these women. Our trial involved infertile women with a low risk of tubal disease. These women were younger than 39 years of age and did not have known endocrinologic diseases, and our findings should not be generalized to infertile women who do not share these features.
The results of previous studies directly comparing the therapeutic effect of oil-based contrast with water-based contrast during hysterosalpingography were conflicting, [8] [9] [10] [11] [12] with the largest and most robust trial 12 showing no effect, but these studies had methodologic limitations. Our trial was more than twice as large as the largest previous trial and had a very low rate of loss to follow-up (1%).
The underlying mechanisms by which oil contrast might enhance fertility are unclear. Some studies suggest that tubal-patency testing with an oily medium will flush debris and dislodge mucus plugs from undamaged tubes. Two previous trials involving women with normal fallopian tubes showed significantly higher pregnancy rates after tubal flushing with oil contrast than with no tubal-patency testing. 4, 6 Also, the oil contrast might have an effect on peritoneal macrophage activity and on endometrial receptivity, thereby enhancing fertility by an implantation-mediated mechanism. 16, 17 Since we observed an effect that continued to persist over multiple menstrual cycles, we consider a direct endometrial effect unlikely.
Tubal flushing with hysterosalpingography during a fertility workup is minimally invasive and inexpensive, as compared with IVF. The 10-percentage-point increase in the clinical pregnancy rate after the use of oil contrast corresponds with a number needed to treat of 10. Data from a formal cost-effectiveness analysis of the potential cost advantage are lacking.
The safety of the use of oil contrast must be considered. There is a theoretical risk of intravasation of the oil contrast with a subsequent allergic reaction or fat embolism. A case report has described intravasation of oil contrast with a subsequent fat embolism, which resolved with supportive measures. 18 However, this is a rare complication; no cases were observed in our Oil or Water Contr ast for Hysterosalpingogr aphy trial nor in other trials involving hysterosalpingography with oil contrast. 19 In our trial, three infants in the oil group and none in the water group had congenital abnormalities. This finding is probably due to chance; the frequency of congenital anomalies with oil contrast was not greater than rates reported in the general population, and we are unaware of other data suggesting an increased risk of congenital anomalies with oil contrast.
New techniques for outpatient tubal testing have been introduced, including hysterosalpingofoam sonography. 20, 21 Data to assess the effects of the use of oil contrast for ultrasonographybased tubal tests or tubal flushing with oil contrast after ultrasonographic examination on rates of pregnancy and live births are lacking.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
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